Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly.

EBioMedicine · 2019 · PMC6562173 · PMID 30975543

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

clearly significantno p-value reported

We performed statistics in the Lanreotide group of patients, and again differences in ARF levels were clearly significant between Group 0 (Resistant) and Group 1 (Responsive), in spite of their reduced number.

also in 627 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.